| Literature DB >> 29109958 |
Kiyonori Ito1, Susumu Ookawara1, Tomohisa Okochi2, Yuichiro Ueda1, Masaya Kofuji3, Hideyuki Hayasaka3, Takayuki Uchida3, Haruhisa Miyazawa1, Katsunori Yanai1, Hiroki Ishii1, Taisuke Kitano1, Mitsutoshi Shindo1, Keiji Hirai1, Yoshio Kaku1, Taro Hoshino1, Osamu Tanaka2, Kaoru Tabei4, Yoshiyuki Morishita1.
Abstract
BACKGROUND: Near-infrared spectroscopy revealed that the regional saturation of oxygen (rSO2) in cerebral tissue is lower in hemodialysis (HD) patients than in healthy subjects. However, no study has examined the changes in cerebral oxygenation by aortic arch calcification (AAC) progression in HD patients.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29109958 PMCID: PMC5646289 DOI: 10.1155/2017/2852514
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Baseline characteristics by AAC grade.
| AAC grade | Grade 0 | Grade 1 | Grade 2 | Grade 3 |
|---|---|---|---|---|
|
| 23 | 24 | 30 | 27 |
| Sex (men), | 18 (78) | 20 (83) | 21 (70) | 21 (78) |
| Age, years | 64 ± 11 | 64 ± 10 | 71 ± 8c | 70 ± 7 |
| HD duration, years | 2.6 ± 5.7 | 5.0 ± 7.6 | 4.3 ± 7.5 | 6.7 ± 5.5 |
| Primary disease, | ||||
| Diabetes mellitus | 11 (48) | 7 (29) | 20 (70)c | 13 (48) |
| Nephrosclerosis | 2 (9) | 4 (17) | 4 (12) | 5 (19) |
| Chronic glomerulonephritis | 8 (34) | 8 (33) | 4 (12) | 3 (11) |
| Others | 2 (9) | 5 (21) | 2 (6) | 6 (22) |
| Medical history, | ||||
| Ischemic heart disease | 3 (13) | 10 (42) | 8 (28) | 20 (74)bd |
| Cerebral infarction | 4 (17) | 8 (33) | 4 (14) | 4 (15) |
| Smoking | 12 (52) | 22 (92)a | 17 (61) | 20 (74) |
| Body mass index, kg/m2 | 22 ± 4 | 23 ± 3 | 22 ± 3 | 23 ± 3 |
| Systolic BP, mmHg | 145 ± 23 | 139 ± 18 | 150 ± 20 | 137 ± 23 |
| Diastolic BP, mmHg | 79 ± 15 | 78 ± 13 | 73 ± 13 | 69 ± 15 |
| Pulse pressure, mmHg | 66 ± 16 | 62 ± 18 | 77 ± 20c | 69 ± 14 |
| Heart rate, per min | 76 ± 11 | 75 ± 15 | 71 ± 16 | 73 ± 12 |
| Oxygen saturation, % | 96 ± 1 | 95 ± 2 | 94 ± 5 | 95 ± 3 |
|
| ||||
| Medication, | ||||
|
| ||||
| RAS blocker (ACEI and/or ARB) | 12 (52) | 15 (63) | 17 (57) | 14 (52) |
| Calcium channel blocker | 14 (61) | 15 (63) | 22 (73) | 15 (56) |
| Beta blocker | 8 (35) | 12 (50) | 19 (63) | 15 (56) |
| Vitamin D analog | 11 (48) | 10 (42) | 13 (43) | 11 (41) |
| Phosphate binder | 15 (65) | 13 (54) | 19 (63) | 18 (67) |
| Calcium-containing phosphate binder | 14 | 10 | 15 | 13 |
| Non-calcium-containing phosphate binder | 4 | 7 | 10 | 13 |
| Cinacalcet | 1 (4) | 1 (4) | 3 (10) | 4 (15) |
| Statin | 5 (22) | 8 (33) | 10 (33) | 12 (44) |
| Antiplatelet agents | 8 (35) | 11 (46) | 13 (43) | 19 (70) |
| Erythropoiesis stimulating agent | 21 (91) | 22 (92) | 30 (100) | 24 (89) |
|
| ||||
| Albumin, g/dL | 3.3 ± 0.6 | 3.2 ± 0.5 | 3.1 ± 0.5 | 2.9 ± 0.6a |
| Serum sodium, mEq/L | 138 ± 4 | 137 ± 5 | 137 ± 3 | 137 ± 4 |
| Serum potassium, mEq/L | 4.4 ± 0.8 | 4.1 ± 0.8 | 4.2 ± 0.8 | 4.1 ± 0.5 |
| Serum calcium, mg/dL | 8.3 ± 0.7 | 8.9 ± 1.1 | 8.5 ± 1.1 | 8.8 ± 0.9 |
| Serum phosphate, mg/dL | 4.8 ± 1.2 | 4.4 ± 1.5 | 4.8 ± 1.3 | 4.4 ± 1.3 |
| BUN, mg/dL | 60 ± 14 | 55 ± 26 | 52 ± 20 | 51 ± 17 |
| Cr, mg/dL | 9.1 ± 2.2 | 8.3 ± 2.2 | 8.5 ± 2.4 | 8.2 ± 2.2 |
| Hb, g/dL | 9.9 ± 1.3 | 9.9 ± 1.6 | 9.4 ± 1.5 | 9.3 ± 1.5 |
| Blood glucose, mg/dL | 159 ± 73 | 149 ± 74 | 133 ± 37 | 152 ± 48 |
| HbA1c, % | 5.5 ± 1.0 | 5.5 ± 0.8 | 5.8 ± 1.0 | 5.7 ± 0.8 |
| Total cholesterol, mg/dL | 156 ± 32 | 148 ± 39 | 151 ± 40 | 149 ± 32 |
| HDL cholesterol, mg/dL | 47 ± 20 | 43 ± 16 | 45 ± 14 | 36 ± 14 |
| Non-HDL cholesterol, mg/dL | 109 ± 24 | 107 ± 29 | 105 ± 36 | 114 ± 29 |
| LDL cholesterol, mg/dL | 84 ± 23 | 77 ± 26 | 80 ± 31 | 88 ± 28 |
| Triglyceride, mg/dL | 96 ± 45 | 111 ± 33 | 100 ± 54 | 117 ± 57 |
| C-reactive protein, mg/dL | 0.7 ± 1.4 | 3.4 ± 8.8 | 1.2 ± 1.6 | 3.2 ± 4.9 |
|
| ||||
| Cerebral rSO2 value, % | 53.7 ± 8.3 | 50.1 ± 10.1 | 48.3 ± 8.6 | 43.2 ± 8.8bc |
AAC, aortic arch calcification; HD, hemodialysis; BP, blood pressure; RAS, renin-angiotensin system; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BUN, blood urea nitrogen; Cr, creatinine; Hb, hemoglobin; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; LDL, low density lipoprotein; rSO2, regional saturation of oxygen. aSignificant versus the AAC grade 0 group (p < 0.05). bSignificant versus the AAC grade 0 group (p < 0.01). cSignificant versus the AAC grade 1 group (p < 0.05). dSignificant versus the AAC grade 2 group (p < 0.01).
Figure 1Association between AAC grade and cerebral rSO2 value. AAC, aortic arch calcification; rSO2, regional saturation of oxygen.
Multivariate regression analysis for cerebral rSO2 value.
| Univariate analysis |
| Multivariate analysis |
| |
|---|---|---|---|---|
| Odds ratio (95% CI) | Odds ratio (95% CI) | |||
| Age | 1.095 (0.503–2.386) | 0.819 | ||
| Smoking (yes versus no) | 2.488 (1.037–5.952) | 0.039 | 4.132 (1.414–12.048) | 0.009 |
| Systolic BP | 2.013 (0.922–4.394) | 0.078 | — | 0.083 |
| Diastolic BP | 1.467 (0.677–3.178) | 0.330 | ||
| Serum calcium | 0.576 (0.264–1.255) | 0.164 | — | 0.801 |
| Serum phosphate | 2.779 (1.256–6.149) | 0.011 | 3.487 (1.34–9.090) | 0.010 |
| HDL cholesterol | 1.535 (0.684–3.444) | 0.298 | ||
| LDL cholesterol | 0.433 (0.192–0.977) | 0.042 | — | 0.148 |
| Triglyceride | 0.690 (0.308–1.546) | 0.367 | ||
| Blood glucose | 0.440 (0.198–0.980) | 0.043 | — | 0.072 |
| HbA1c | 0.670 (0.292–1.534) | 0.342 | ||
| C-reactive protein | 0.369 (0.143–0.952) | 0.036 | — | 0.390 |
| AAC grade (versus grade 0) | ||||
| Grade 1 | 1.338 (0.4111–4.366) | 0.627 | ||
| Grade 2 | 2.141 (0.700–6.535) | 0.179 | 4.626 (1.241–17.244) | 0.023 |
| Grade 3 | 4.444 (1.353–14.705) | 0.012 | 4.333 (1.134–16.551) | 0.032 |
BP, blood pressure; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; LDL, low density lipoprotein; rSO2, regional saturation of oxygen; AAC, aortic arch calcification; CI, confidence interval.